Q-omics provides the consensus-scored RPL32P22 profile across patient tissues and cancer cell-line models. RPL32P22 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPL32P22 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, RPL32P22 RNA expression shows 17,531 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, LIHC, and THYM as cancer lineages where RPL32P22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL32P22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL32P22 survival associations across molecular data types. RPL32P22 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL32P22 RNA expression–survival associations across cancer types. High RPL32P22 expression shows unfavorable associations in DLBC, STAD and THCA, but favorable associations in MESO, BLCA and CESC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for RPL32P22 RNA expression.
This table summarizes RPL32P22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL32P22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL32P22 shows lower tumor expression in BRCA and higher tumor expression in LIHC, PAAD, COAD and LUSC. The LIHC box plot shows higher RPL32P22 RNA expression in tumor versus normal tissue (log2 FC = +0.094, t-test p < 0.001).
This table shows molecular features associated with RPL32P22 in patient tissues and cancer cell lines. In patient samples, RPL32P22 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
